Form 4: Oncocyte Corp CEO Josh Riggs Reports Stock Unit Transaction
SEC Form 4 Filing
Oncocyte Corp CEO Josh Riggs reports the acquisition and disposal of restricted stock units.
Summary
- On March 26, 2025, Oncocyte Corp CEO Josh Riggs reported a transaction involving restricted stock units.
- Riggs acquired 188,679 restricted stock units.
- Simultaneously, Riggs disposed of 188,679 restricted stock units.
- Following the reported transactions, Riggs directly owns 188,679 derivative securities.
- The restricted stock units vest in four equal installments on the one-, two-, three-, and four-year anniversaries of the grant date, contingent upon continuous service.
Sentiment
Score: 5
Explanation: This is a standard SEC filing related to stock transactions, indicating a neutral sentiment.
Industry Context
This is a routine disclosure related to executive compensation and equity ownership, common in publicly traded companies.
Stakeholder Impact
- The transaction may have a minor impact on shareholder perception of executive compensation and alignment with company performance.
Key Dates
| Date | Description |
|---|---|
| 03/26/2025 | Date of transaction involving restricted stock units. |
| 03/28/2025 | Date of signature for the report. |
Keywords
Form 4, Oncocyte Corp, Josh Riggs, Restricted Stock Units, OCX, Beneficial Ownership, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.